Testing effectiveness (Phase 2)Looking for participantsNCT04422912
What this trial is testing
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Who this might be right for
Pemphigus Vulgaris
Cabaletta Bio 40